iRadimed Corporation
IRMD Healthcare Medical Devices
iRadimed Corporation’s revenue for fiscal 2025 (year ended December 2025) was $83.8 million, up 14.4% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS fell 8.89% and free cash flow grew 11.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years.
Follow IRMD
iRadimed Corporation (IRMD) EV/Sales
As of 16 October 2026, iRadimed Corporation (IRMD) trades at a EV/Sales of 12.4×. Over the past ten years it has ranged from 1.9× (March 2017) to 15.4× (February 2026); the current reading is higher than 92% of that period. That is above the Medical Devices industry median of 2.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 14.2× | 60.84% |
| FY2024 | 8.8× | 5.64% |
| FY2023 | 8.3× | 48.12% |
| FY2022 | 5.6× | (53.70%) |
| FY2021 | 12.1× | 71.68% |
| FY2020 | 7.1× | 25.31% |
| FY2019 | 5.6× | (24.86%) |
| FY2018 | 7.5× | 27.16% |
| FY2017 | 5.9× | 101.17% |
| FY2016 | 2.9× | (67.02%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 13.5× | (1.05%) |
| Mar 2026 | 13.6× | (3.87%) |
| Dec 2025 | 14.2× | 34.29% |
| Sep 2025 | 10.5× | 15.70% |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LMRI Lumexa Imaging Holdings, Inc. compare | 1.0× |
| ENOV Enovis Corporation compare | 1.0× |
| TNDM Tandem Diabetes Care, Inc. compare | 1.2× |
| IART Integra LifeSciences Holdings Corporation compare | 1.6× |
| BVS Bioventus Inc. compare | 1.9× |
| PRCT PROCEPT BioRobotics Corporation compare | 2.5× |
| AORT Artivion, Inc. compare | 2.9× |
| CBLL CeriBell, Inc. compare | 8.3× |
| IRMD iRadimed Corporation | 12.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)